Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status

Bozec, Alexandre; Culié, Dorian; Poissonnet, G.; Démard, F; Dassonville, O.

doi:10.3390/cancers13215456

Cited by 9 publications

(3 citation statements)

References 101 publications

(201 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of these differences, both HPV− and HPV+ patients receive the same treatment [ 5 , 7 , 8 ]. The current curative standard of treatment for locally advanced OPSCC is an intense chemoradiation regimen causing considerable unwanted side effects [ 9 , 10 ]. As the prevalence of HPV+ OPSCC increases, it becomes crucial to investigate the possibility of treating HPV+ tumours with a less aggressive approach to reduce treatment-related toxicity [ 5 , 7 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review

Chen,

Lauwers,

Verduijn

et al. 2024

Cancers

View full text Add to dashboard Cite

Human papillomavirus (HPV) is an important risk factor for oropharyngeal squamous cell carcinoma (OPSCC). HPV-positive (HPV+) cases are associated with a different pathophysiology, microstructure, and prognosis compared to HPV-negative (HPV−) cases. This review aimed to investigate the potential of magnetic resonance imaging (MRI) to discriminate between HPV+ and HPV− tumours and predict HPV status in OPSCC patients. A systematic literature search was performed on 15 December 2022 on EMBASE, MEDLINE ALL, Web of Science, and Cochrane according to PRISMA guidelines. Twenty-eight studies (n = 2634 patients) were included. Five, nineteen, and seven studies investigated structural MRI (e.g., T1, T2-weighted), diffusion-weighted MRI, and other sequences, respectively. Three out of four studies found that HPV+ tumours were significantly smaller in size, and their lymph node metastases were more cystic in structure than HPV− ones. Eleven out of thirteen studies found that the mean apparent diffusion coefficient was significantly higher in HPV− than HPV+ primary tumours. Other sequences need further investigation. Fourteen studies used MRI to predict HPV status using clinical, radiological, and radiomics features. The reported areas under the curve (AUC) values ranged between 0.697 and 0.944. MRI can potentially be used to find differences between HPV+ and HPV− OPSCC patients and predict HPV status with reasonable accuracy. Larger studies with external model validation using independent datasets are needed before clinical implementation.

show abstract

Section: Introductionmentioning

confidence: 99%

MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review

Chen,

Lauwers,

Verduijn

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Factors other than HB explain a portion of the increased survival in HPV related HNC. These factors include but are not limited to decreased morbidity due to decreased alcohol and tobacco use, the increased sensitivity oof HPV related tumors to radiation and chemotherapy, as well as a possibly a lower risk for other cancers due to the decreased amount and duration of smoking and alcohol consumption in the population [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

“…Although pretreatment HBs such as tobacco use, diet, and physical activity level predict survival among HNC patients, little is understood about the HBs of survivors of HNC. What is known regarding HBs primarily focuses on tobacco and alcohol use among non-HPV associated HNC survivors [ 12 , 18 , 19 ]. In addition, very little is known about the HBs of individuals with HPV-associated HNC, an unfortunate gap in our ability to plan effective interventions for improving both survival and quality of life of this growing subpopulation of cancer survivors.…”

Section: Introductionmentioning

confidence: 99%

Health behaviors among head and neck cancer survivors

McMenamin

Gottschalk

Pucci

et al. 2023

J Health Popul Nutr

View full text Add to dashboard Cite

Purpose To determine to what extent head and neck cancer (HNC) survivors participate in health behaviors (HBs) recommended by the National Cancer Center Network (NCCN®). Methods Participants identified through the tumor registries at the Abramson Cancer Center (ACC), University of Pennsylvania and affiliated sites. Eligibility: (a) diagnosis and treatment HNC; (b) aged 18 to 70 years; (c) ≥ 1-year post-diagnosis; (d) human papillomavirus (HPV) status confirmed; (e) ability to understand written English. Potential participants received an explanation of the study, informed consent, self-reported questionnaire, and self-addressed stamped envelope. Results 451 individuals eligible, 102 (23%) agreed to participate, HPV positive (74%). Current smoking rare (7%), historical use common (48%). Current alcohol use common (65%), average 2.1 drinks/day, 12 days/month. 22% binge drank with an average of 3.5 binge-drinking sessions per month. Nutritional behavior mean 7.1 (range 0–16), lower scores indicating better nutrition. Body mass index (BMI) 59% overweight/obese. Adequate aerobic exercise 59%, adequate strength and flexibility 64%. Leisure time activity, 18% sedentary, 19% moderately active, 64% active. All participants reported having a primary care physician, 92% seen in the previous 12 months. Conclusions Most HNC survivors participated in some HBs. Current smoking rarely reported, binge drinking and high BMI most common negative HBs. Opportunities remain to improve dietary and exercise behaviors. Implications for cancer survivors The NCCN® has outlined HBs that decrease likelihood of cancer survivors developing comorbidities that could impact overall survival. It is incumbent on healthcare providers to educate and encourage cancer survivors to participate in these HBs.

show abstract

Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities

Liu

Yang

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Messenger RNA (mRNA) holds great potential in developing immunotherapy, protein replacement, and genome editing. In general, mRNA does not have the risk of being incorporated into the host genome and does not need to enter the nucleus for transfection, and it can be expressed even in nondividing cells. Therefore, mRNA‐based therapeutics provide a promising strategy for clinical treatment. However, the efficient and safe delivery of mRNA remains a crucial constraint for the clinical application of mRNA therapeutics. Although the stability and tolerability of mRNA can be enhanced by directly retouching the mRNA structure, there is still an urgent need to improve the delivery of mRNA. Recently, significant progress has been made in nanobiotechnology, providing tools for developing mRNA nanocarriers. Nano‐drug delivery system is directly used for loading, protecting, and releasing mRNA in the biological microenvironment and can be used to stimulate the translation of mRNA to develop effective intervention strategies. In the present review, we summarized the concept of emerging nanomaterials for mRNA delivery and the latest progress in enhancing the function of mRNA, primarily focusing on the role of exosomes in mRNA delivery. Moreover, we outlined its clinical applications so far. Finally, the key obstacles of mRNA nanocarriers are emphasized, and promising strategies to overcome these obstacles are proposed. Collectively, nano‐design materials exert functions for specific mRNA applications, provide new perception for next‐generation nanomaterials, and thus revolution of mRNA technology.

show abstract

Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status

Cited by 9 publications

References 101 publications

MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review

MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review

Health behaviors among head and neck cancer survivors

Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities

Contact Info

Product

Resources

About